Immobilized enzyme, preparation method and use thereof

Abstract

Provided is an immobilized enzyme, a preparation method and use thereof. The immobilized enzyme includes an enzyme and an amino resin carrier for immobilizing the enzyme, and the enzyme is selected from any one of the following enzymes: transaminase, ketoreductase, monooxygenase, ammonia-lyase, ene reductase, imine reductase, amino acid dehydrogenase, and nitrilase. The amino resin carrier is an amino resin carrier modified by a cross-linking agent, and the cross-linking agent is a cross-linking agent treated by a polymer. By means of modifying the amino resin carrier with the cross-linking agent treated by the polymer, the enzyme immobilized on the amino resin carrier may easily form a network cross-linking, such that the immobilization effect of the enzyme is more stable, thereby the recycling efficiency of the enzyme is improved.

Claims

1. An immobilized enzyme, comprising an enzyme and the enzyme is immobilized on an amino resin carrier, wherein the enzyme is selected from any one of the group consisting of a transaminase, a ketoreductase, a monooxygenase, an ammonia lyase, an ene reductase, an imine reductase, an amino acid dehydrogenase and a nitrilase, and the amino resin carrier is modified by a cross-linking agent, and the cross-linking agent is a macromolecular polymer modified cross-linking agent.

2. The immobilized enzyme as claimed in claim 1, wherein the transaminase is derived from Chromobacterium violaceum DSM3019, Aspergillus fumigatus, or Arthrobacter citreus, preferably, the transaminase derived from the Chromobacterium violaceum DSM30191 is a mutant with a sequence as shown in SEQ ID NO: 2 or SEQ ID NO: 3; and the transaminase derived from the Arthrobacter citreus is a mutant with a sequence as shown in SEQ ID NO: 5 or SEQ ID NO: 6; preferably, the ketoreductase is derived from Acetobacter sp. CCTCC M209061 or Candida macedoniensis AKU4588, more preferably the ketoreductase derived from the Acetobacter sp. CCTCC M209061 is a mutant with a sequence as shown in SEQ ID NO: 8 or SEQ ID NO: 9; preferably, the monooxygenase is a cyclohexanone monooxygenase derived from Rhodococcus sp. Phil, or a cyclohexanone monooxygenase derived from Brachymonas petroleovorans, or a monooxygenase derived from Rhodococcus ruber-SD1, more preferably, the cyclohexanone monooxygenase derived from the Rhodococcus sp. Phil is a mutant with a sequence as shown in SEQ ID NO: 11 or SEQ ID NO: 12; and the cyclohexanone monooxygenase derived from the Rhodococcus ruber-SDl is a mutant with a sequence as shown in SEQ ID NO: 14 or SEQ ID NO: 15; preferably, the ammonia lyase is derived from photorhabdus luminescens or Solenostemon scutellarioides; preferably, the ene reductase is derived from Saccharomyces cerevisiae or Chryseobacterium sp. CA49; preferably, the imine reductase is derived from Streptomyces sp or Bacillus cereus; preferably, the amino acid dehydrogenase is a leucine dehydrogenase derived from Bacillus cereus or a phenylalanine dehydrogenase derived from Bacillus sphaericus; and preferably, the nitrilase is derived from Aspergillus niger CBS 513.88 or Neurospora crassa OR74A .

3. The immobilized enzyme as claimed in claim 1, wherein the amino resin carrier is an amino resin carrier with a C2 or C4 linker arm.

4. The immobilized enzyme as claimed in claim 1, wherein the cross-linking agent is a glutaraldehyde, and the macromolecular polymer is a PEG or a PEI.

5. A preparation method for an immobilized enzyme, comprising: performing pretreatment on a cross-linking agent with a macromolecular polymer, to obtain a modified cross-linking agent; performing modification on an amino resin carrier with the treated cross-linking agent, to obtain a modified carrier; and immobilizing an enzyme to on the modified carrier, to obtain the immobilized enzyme; wherein the enzyme is selected from any one of the group consisting of a transaminase, a ketoreductase, a monooxygenase, an ammonia lyase, an ene reductase, an imine reductase, an amino acid dehydrogenase and a nitrilase.

6. The preparation method as claimed in claim 5, wherein the transaminase is derived from Chromobacterium violaceum DSM3019, Aspergillus fumigatus, or Arthrobacter citreus, preferably, the transaminase derived from the Chromobacterium violaceum DSM30191 is a mutant with a sequence as shown in SEQ ID NO: 2 or SEQ ID NO: 3; and the transaminase derived from the Arthrobacter citreus is a mutant with a sequence as shown in SEQ ID NO: 5 or SEQ ID NO: 6; preferably, the ketoreductase is derived from Acetobacter sp. CCTCC M209061 or Candida macedoniensis AKU4588, more preferably the ketoreductase derived from the Acetobacter sp. CCTCC M209061 is a mutant with a sequence as shown in SEQ ID NO: 8 or SEQ ID NO: 9; preferably, the monooxygenase is a cyclohexanone monooxygenase derived from Rhodococcus sp. Phil, or a cyclohexanone monooxygenase derived from Brachymonas petroleovorans, or a monooxygenase derived from Rhodococcus ruber-SD1 more preferably, the cyclohexanone monooxygenase derived from the Rhodococcus sp. Phil is a mutant with a sequence as shown in SEQ ID NO: 11 or SEQ ID NO: 12; and the cyclohexanone monooxygenase derived from the Rhodococcus ruber-SD1 is a mutant with a sequence as shown in SEQ ID NO: 14 or SEQ ID NO: 15; preferably, the ammonia lyase is derived from photorhabdus luminescens or Solenostemon scutellarioides; preferably, the ene reductase is derived from Saccharomyces cerevisiae or Chryseobacterium sp. CA49; preferably, the imine reductase is derived from Streptomyces sp or Bacillus cereus; preferably, the amino acid dehydrogenase is a leucine dehydrogenase derived from Bacillus cereus or a phenylalanine dehydrogenase derived from Bacillus sphaericus; and preferably, the nitrilase is derived from Aspergillus niger CBS 513.88 or Neurospora crassa OR74A .

7. The preparation method as claimed in claim 5, wherein the amino resin carrier is an amino resin carrier with a C2 or C4 linker arm.

8. The preparation method as claimed in claim 5, wherein the cross-linking agent is a glutaraldehyde, and the macromolecular polymer is a PEG or a PEI.

9. The preparation method as claimed in claim 8, wherein a mass ratio of the PEG and the glutaraldehyde is 1:1-10:1, preferably 2:1-5:1.

10. (canceled)

11. (canceled)

12. The immobilized enzyme as claimed in claim 1, wherein the amino resin carrier is selected from any one of the group consisting of: SEPLITE® LX1000EA, LX1000HA, LX1000NH, LX1000EPN, HM100D, Purolite® Lifetech™ ECR8309, ECR8409, ECR8305, ECR8404, ECR8315, ECR8415, HECHENG® ESR-1, ESR-3, ESR-5 and ESR-8.

13. The immobilized enzyme as claimed in claim 4, wherein the PEG is selected from any one of PEG400-PEG6000.

14. The immobilized enzyme as claimed in claim 4, wherein the PEI is selected from a PEI with 3-70 KDa of a molecular weight.

15. The immobilized enzyme as claimed in claim 4, wherein a mass ratio of the PEG and the glutaraldehyde is 1:1-10:1, further preferably 2:1-5:1.

16. The immobilized enzyme as claimed in claim 4, wherein a mass ratio of the PEI and the glutaraldehyde is 3:1-1:5.

17. The immobilized enzyme as claimed in claim 16, wherein the mass ratio of the PEI and the glutaraldehyde is 1:1-1:2.

18. The preparation method as claimed in claim 7, wherein the amino resin carrier is selected from any one of the group consisting of: SEPLITE® LX1000EA, LX1000HA, LX1000NH, LX1000EPN, HM100D, Purolite® Lifetech™ ECR8309, ECR8409, ECR8305, ECR8404, ECR8315, ECR8415, HECHENG® ESR-1, ESR-3, ESR-5 and ESR-8.

19. The preparation method as claimed in claim 8, wherein the PEG is selected from any one of PEG400-PEG6000.

20. The preparation method as claimed in claim 8, wherein the PEI is selected from a PEI with 3-70 KDa of a molecular weight.

21. The preparation method as claimed in claim 9, wherein a mass ratio of the PEI and the glutaraldehyde is 3:1 -1:5.

22. The preparation method as claimed in claim 21, wherein a mass ratio of the PEI and the glutaraldehyde is 1:1-1:2.

Description

DETAILED DESCRIPTION OF THE EMBODIMENTS

[0030] It should be noted that embodiments in the present application and features of the embodiments may be combined with each other in the case without conflicting. The present invention is described in detail below with reference to the embodiments.

[0031] Amino resin: the resin may be pre-activated with a glutaraldehyde before being used for enzyme immobilization, and then an aldehyde group on the carrier reacts with an amino group on an enzyme molecule to form a Schiff base, to construct a firm multi-site covalent bonding site. It has a long or short amino linking arm.

[0032] Enzyme adsorption resin carrier: this type of the resin carrier immobilizes the enzyme on the surface of the water-insoluble carrier resin by a principle of physical adsorption. The immobilization method is mild, hardly changes the conformation of the enzyme, and does not damage an active center of the enzyme. It is especially suitable for the immobilization in an organic solvent or a hydrophobic solvent, and any additional reagents are not required in the immobilization process.

[0033] The ion adsorption enzyme carrier resin may form an ionic interaction force with the enzyme molecule within the higher ionic strength, thereby the enzyme is adsorbed and immobilized. The adsorption thereof is reversible, but an adsorption force is stronger than the Van Der Waals force. While the enzyme activity disappears, the carrier may be recycled and reused.

[0034] As mentioned in the background, there are still many enzymes that do not achieve the immobilization in existing technologies, and the recycling rate is limited. In order to improve this situation, in a typical embodiment of the present application, an immobilized enzyme is provided, and the immobilized enzyme includes an enzyme and an amino resin carrier for immobilizing the enzyme, and the enzyme is selected from any one of the following enzymes: transaminase, ketoreductase, monooxygenase, ammonia-lyase, ene reductase, imine reductase, amino acid dehydrogenase, and nitrilase, the amino resin carrier is an amino resin carrier modified by a cross-linking agent, and the cross-linking agent is a cross-linking agent treated by a polymer.

[0035] The amino resin carrier is modified by the cross-linking agent treated with the polymer, it is beneficial to make the enzyme immobilized on it to form a network cross-linking, thereby the immobilization effect of the above enzyme is more stable, and the recycling efficiency of these enzymes is improved.

[0036] In the above immobilized enzymes, the immobilization form of the enzyme on the amino resin carrier is not limited, and it may be covalently immobilized, or non-covalently immobilized. The covalently immobilized form is more stable, so in a preferred embodiment, the enzyme is covalently immobilized on the amino resin carrier.

[0037] The specific type of the enzyme in the above immobilized enzymes is selected from any one of transaminase (referred to as TA in the present application), ketoreductase (referred to as KRED in the present application), cyclohexanone monooxygenase (referred to as CHMO in the present application), phenylalanine ammonia lyase (referred to as PLA in the present application), ene reductase (referred to as ERED in the present application), imine reductase (referred to as IRED in the present application), amino acid dehydrogenase (referred to as AADH in the present application) and nitrilase (referred to as NIT in the present application).

[0038] The chemical process involved in reactions of the above enzymes is briefly described as follows:

##STR00001##

##STR00002##

##STR00003##

##STR00004##

##STR00005##

##STR00006##

##STR00007##

##STR00008##

[0039] R, R1 and R2 in the above reaction formula may be independently selected from H, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted heterocycloalkyl, or R1 and a heterocycle to which it is linked form a fused ring system.

[0040] The specific types or species sources of the above enzymes are also not particularly limited, and the types used may be selected according to actual needs. In a preferred embodiment of the present application, the transaminase is derived from Chromobacterium violaceum DSM30191, Aspergillus fumigatus, or Arthrobacter citreus, preferably, the transaminase derived from the Chromobacterium violaceum DSM30191 is a mutant with a sequence as shown in SEQ ID NO: 2 or SEQ ID NO: 3; and the transaminase derived from the Arthrobacter citreus is a mutant with a sequence as shown in SEQ ID NO: 5 or SEQ ID NO: 6.

[0041] In another preferred embodiment of the present application, the ketoreductase is derived from Acetobacter sp. CCTCC M209061 or Candida macedoniensis AKU4588, more preferably the ketoreductase derived from the Acetobacter sp. CCTCC M209061 is a mutant with a sequence as shown in SEQ ID NO: 8 or SEQ ID NO: 9.

[0042] In another preferred embodiment of the present application, the monooxygenase is a cyclohexanone monooxygenase derived from Rhodococcus sp. Phi1, or a cyclohexanone monooxygenase derived from Brachymonas petroleovorans, or a monooxygenase derived from Rhodococcus ruber-SD1, more preferably, the cyclohexanone monooxygenase derived from the Rhodococcus sp. Phi1 is a mutant with a sequence as shown in SEQ ID NO: 11 or SEQ ID NO: 12; and the cyclohexanone monooxygenase derived from the Rhodococcus ruber-SD1 is a mutant with a sequence as shown in SEQ ID NO: 14 or SEQ ID NO: 15.

[0043] In another preferred embodiment of the present application, the ammonia lyase is derived from photorhabdus luminescens or Solenostemon scutellarioides; preferably, the ene reductase is derived from Saccharomyces cerevisiae or Chryseobacterium sp. CA49; preferably, the imine reductase is derived from Streptomyces sp or Bacillus cereus; preferably, the amino acid dehydrogenase is a leucine dehydrogenase derived from Bacillus cereus or a phenylalanine dehydrogenase derived from Bacillus sphaericus; and preferably, the nitrilase is derived from Aspergillus niger CBS 513.88 or Neurospora crassa OR74A .

[0044] It should be noted that the above enzymes from various sources, if they are not specifically marked as mutants, are all wild-type, and the specific sequences may be obtained and queried from National Center of Biotechnology Information (NCBI).

[0045] The amino resin carrier in the above immobilized enzymes may be a commercially available type. In the present application, preferably the amino resin carrier is an amino resin carrier with a C2 or C4 linking arm. There is also a certain difference in the immobilization effect of the same carrier to the different enzymes. The specific type of the amino resin carrier with the C2 and C4 linking arm may be optimally selected from the existing types according to the different actual enzyme types. In a preferred embodiment of the present application, the amino resin carrier is selected from any one of the group consisting of: LX1000EA, LX1000HA, LX1000NH, LX1000EPN, HM100D, ECR8309, ECR8409, ECR8305, ECR8404, ECR8315, ECR8415, ESR-1, ESR-3, ESR-5 and ESR-8.

[0046] Herein, the LX1000EA, LX1000HA, LX1000NH, LX1000EPN, and HM100D are products of SUNRISE Company, the ECR8309, ECR8409, ECR8305, ECR8404, and ECR8315 are products of Purolite Company, and the ESR-1, ESR-3, ESR-5 and ESR-8 are products of Nankai Synthetic Company.

[0047] In the above types, the LX1000HA, ECR8409 and LX1000EPN carriers have the relatively best immobilization effects on the transaminase; the LX1000HA and ESR-1 carriers have the relatively best immobilization effects on the ketoreductase; the LX1000HA and ECR8409 carriers have the relatively best immobilization effects on the cyclohexanone monooxygenase; the LX1000HA, LX1000EA, ECR8309 and ECR8409 carriers have the relatively best immobilization effects on the ene reductase; the LX1000HA carrier has the relatively best immobilization effect on the nitrilase; the ECR8409 and LX1000EPN have the relatively best immobilization effects on the imine reductase; the LX1000EPN and ECR8309 have the relatively best immobilization effects on the ammonia lyase; and the LX1000HA and ECR8409 carriers have the relatively best immobilization effects on the amino acid dehydrogenase.

[0048] In the above immobilized enzymes, the cross-linking agent is a glutaraldehyde, and the preferred macromolecular polymer is polyethylene glycol (PEG) or polyethylene imine (PEI); preferably, PEG is selected from any one of PEG400~PEG6000; preferably, PEI is selected from PEI with a molecular weight of 3~70 KDa; more preferably, the mass ratio of PEG to the glutaraldehyde is 1:1~10:1, further preferably 2:1~5:1; more preferably, the mass ratio of PEI to the glutaraldehyde is 3:1~1:5, further preferably 1:1~1:2.

[0049] In the above preferred embodiment, the macromolecular polymer PEG or PEI is used to treat the glutaraldehyde, so that an aldehyde group of the glutaraldehyde is covalently bonded with a hydroxyl group of PEG or an amino group of PEI, and finally a network structure in which the aldehyde group, and the amino group/hydroxyl group are dispersed is formed, each functional group in this network structure is combined with an enzyme protein through covalent interaction, hydrogen bond interaction, ionic interaction, and hydrophobic interaction and the like, rather than just the covalent interaction like the glutaraldehyde. The covalent bond interaction may easily destroy the activity of the enzyme.

[0050] The specific molecular weight of PEG or PEI may be reasonably optimally selected according to the different types of the immobilized enzymes. Within the above molecular weight range, the immobilization effect on the existing enzymes is relatively better. While the mass ratio of the glutaraldehyde treated with PEG or PEI is within the above range, the distribution of the aldehyde group and the amino group/hydroxyl group in a cross-linking agent-polymer composition with the network structure is relatively uniform. If a proportion of the macromolecular polymer is too low, there are more free aldehyde groups, and a spacing between the aldehyde groups is small, a covalent bonding mode dominates the combining with the enzyme protein, so that the enzyme activity is relatively low. If the macromolecular polymer ratio is too high, the amount of the free aldehyde groups is too small, and the covalent bonding becomes weaker while combined with the enzyme protein, and the stability of the immobilized enzyme is decreased. In a preferred range, in the cross-linking agent-polymer composition with the network structure, the ratio and distribution of the aldehyde group to the amino group/hydroxyl group are better, and in the combination with the enzyme, the covalent interaction, the hydrogen bond interaction, the ionic interaction and the hydrophobic interaction and the like are combined in the better ratio, to further improve the activity and stability of the immobilized enzyme. Other macromolecular polymers with hydroxyl functional groups, such as polyvinyl alcohol, may also be used, but the water solubility thereof is poor at a room temperature, and the application effect is limited, so PEG is preferred. Other macromolecular polymers with amino functional groups, such as a polyetheramine, also have a certain effect, but it is considered that it is easy to cause the denaturation of the enzyme protein to a certain extent, PEI is preferred.

[0051] In a second typical embodiment of the present application, a preparation method for an immobilized enzyme is provided, and the preparation method includes: performing pretreatment on a cross-linking agent with a macromolecular polymer, to obtain a treated cross-linking agent; performing modification on an amino resin carrier with the treated cross-linking agent, to obtain a modified carrier; and immobilizing an enzyme on the modified carrier, to obtain the immobilized enzyme; herein the enzyme is selected from any one of the group consisting of a transaminase, a ketoreductase, a monooxygenase, an ammonia lyase, an ene reductase, an imine reductase, an amino acid dehydrogenase and a nitrilase.

[0052] In the preparation method of the present application, the cross-linking agent has more network structures after being pre-treated with the macromolecular polymer, and then the amino resin carrier is modified by using the cross-linking agent with the more network structures, so that the carrier also has the more network structures. Therefore, while the enzyme is immobilized on the modified carrier, the immobilization effect on the enzyme is more stable.

[0053] In another preferred embodiment of the present application, the transaminase is derived from Chromobacterium violaceum DSM30191, Aspergillus fumigatus, or Arthrobacter citreus, preferably, the transaminase derived from the Chromobacterium violaceum DSM30191 is a mutant with a sequence as shown in SEQ ID NO: 2 or SEQ ID NO: 3; and the transaminase derived from the Arthrobacter citreus is a mutant with a sequence as shown in SEQ ID NO: 5 or SEQ ID NO: 6.

[0054] In another preferred embodiment of the present application, the ketoreductase is derived from Acetobacter sp. CCTCC M209061 or Candida macedoniensis AKU4588, more preferably the ketoreductase derived from the Acetobacter sp. CCTCC M209061 is a mutant with a sequence as shown in SEQ ID NO: 8 or SEQ ID NO: 9.

[0055] In another preferred embodiment of the present application, the monooxygenase is a cyclohexanone monooxygenase derived from Rhodococcus sp. Phi1, or a cyclohexanone monooxygenase derived from Brachymonas petroleovorans, or a monooxygenase derived from Rhodococcus ruber-SD1, more preferably, the cyclohexanone monooxygenase derived from the Rhodococcus sp. Phi1 is a mutant with a sequence as shown in SEQ ID NO: 11 or SEQ ID NO: 12; and the cyclohexanone monooxygenase derived from the Rhodococcus ruber-SD1 is a mutant with a sequence as shown in SEQ ID NO: 14 or SEQ ID NO: 15.

[0056] In another preferred embodiment of the present application, the ammonia lyase is derived from photorhabdus luminescens or Solenostemon scutellarioides; preferably, the ene reductase is derived from Saccharomyces cerevisiae or Chryseobacterium sp. CA49; preferably, the imine reductase is derived from Streptomyces sp or Bacillus cereus; preferably, the amino acid dehydrogenase is a leucine dehydrogenase derived from Bacillus cereus or a phenylalanine dehydrogenase derived from Bacillus sphaericus; and preferably, the nitrilase is derived from Aspergillus niger CBS 513.88 or Neurospora crassa OR74A .

[0057] The enzyme derived from the above species is immobilized on the amino resin carrier modified by the cross-linking agent treated with the macromolecular polymer, as to form the immobilized enzyme which has the relatively better activity and stability, so the number of cycles is also higher.

[0058] In the above preparation method, the amino resin carrier may select a suitable carrier according to the different enzymes. In a preferred embodiment, the amino resin carrier is an amino resin carrier with a C2 or C4 linking arm, preferably, the amino resin carrier is selected from any one of the followings: LX1000EA, LX1000HA, LX1000NH, LX1000EPN, HM100D, ECR8309, ECR8409, ECR8305, ECR8404, ECR8315, ECR8415, ESR-1, ESR-3, ESR-5 and ESR-8. The selection of the above types of case resin carriers is beneficial to the immobilization of the various enzymes.

[0059] In the above preparation method, the cross-linking agent may be optimally selected from the existing types of the cross-linking agents according to actual needs. The main function of the macromolecular polymer is to combine the free aldehyde group in the cross-linking agent, thereby a cross-linking agent-polymer composition with the network structure is formed, as to reduce the influence on the activity of the enzyme to be immobilized.

[0060] In a preferred embodiment, the cross-linking agent is a glutaraldehyde, and the macromolecular polymer is PEG or PEI. Preferably, PEG is selected from any one of PEG400 ~ PEG6000; and preferably, PEI is selected from PEI with a molecular weight of 3~70 KDa.

[0061] In the above preferred embodiment, the specific molecular weight of PEG or PEI may be reasonably optimally selected according to the different types of the immobilized enzymes. Within the above molecular weight range, the immobilization effect on the existing enzymes is relatively better.

[0062] In the above preparation method, the mass ratio of PEG to the glutaraldehyde is 1:1~10:1, preferably 2:1~5:1; and preferably, the mass ratio of PEI to the glutaraldehyde is 3:1~1:5, more preferably 1:1~1:2.

[0063] The macromolecular polymers with the hydroxyl group or the amino group are all suitable for the present application, but PGE or PEI is preferably used in the above embodiments. Other macromolecular polymers with the hydroxyl functional group, such as polyvinyl alcohol, may also be used, but the water solubility thereof is poor at a room temperature, and the application effect is limited, so PEG is preferred. Other macromolecular polymers with the amino functional group, such as polyetheramine, also have a certain effect, but it is considered that it is easy to cause the denaturation of the enzyme protein to a certain extent, PEI is preferred.

[0064] While the mass ratio of the glutaraldehyde treated with PEG or PEI is within the above range, the distribution of the aldehyde group and the amino group/hydroxyl group in the cross-linking agent-polymer composition with the network structure is relatively uniform. If a proportion of the macromolecular polymer is too low, there are more free aldehyde groups, and a spacing between the aldehyde groups is small, a covalent bonding mode dominates the combining with the enzyme protein, so that the enzyme activity is relatively low. If the macromolecular polymer ratio is too high, the amount of the free aldehyde groups is too small, and the covalent bonding becomes weaker while combined with the enzyme protein, and the stability of the immobilized enzyme is decreased. In a preferred range, in the cross-linking agent-polymer composition with the network structure, the ratio and distribution of the aldehyde group to the amino group/hydroxyl group are better, and in the combination with the enzyme, the covalent interaction, the hydrogen bond interaction, the ionic interaction and the hydrophobic interaction and the like are combined in the better ratio, to further improve the activity and stability of the immobilized enzyme.

[0065] In the third typical embodiment of the present application, an application of any one of the above immobilized enzymes or the immobilized enzyme prepared by any one of the above preparation methods in a biocatalytic reaction is provided. The immobilized enzyme has the advantages of high stability and high recycling efficiency, so it may be used repeatedly in a biocatalytic reaction.

[0066] In a more preferred embodiment, the biocatalytic reaction used by the above immobilized enzyme is a continuous biocatalytic reaction or a batch reaction. The immobilized enzyme has the high recycling efficiency, so it is suitable for the continuous biocatalytic reaction, and improves the reaction efficiency.

[0067] The enzyme derived from the above species is immobilized on the amino resin carrier modified by the cross-linking agent treated with the macromolecular polymer, as to form the immobilized enzyme which has the relatively better activity and stability, so the number of cycles is also higher. In a preferred embodiment, the number of cycling times of the above immobilized enzyme under the reaction conditions of an aqueous phase or an organic phase is 6 to 16 times.

[0068] The beneficial effects of the present application are further described below with reference to the specific embodiments.

[0069] The enzymes used in the following embodiments and the sources thereof are shown in Table 1 below. The sequences of some of the enzymes are shown in Tables 2 to 6.

TABLE-US-00001 Short name Enzyme Source TA-Af Transaminase Aspergillus fumigatus TA-Ac Transaminase Arthrobacter citreus TA-Cv Transaminase Chromobacterium violaceum DSM30191 KRED-Ac Ketoreductase Acetobacter sp. CCTCC M209061 KRED-Cm Ketoreductase Candida macedoniensis. AKU4588 CHMO-Bp Cyclohexanone monooxygenase Brachymonas petroleovorans CHMO-Rr Cyclohexanone monooxygenase Rhodococcus ruber-SDI CHMO-Rs Cyclohexanone monooxygenase Rhodococcus sp. Phil ERED-Sc Ene reductase Saccharomyces cerevisiae ERED-Chr Ene reductase Chryseobacterium sp. CA49 NIT-An Nitrilase Aspergillus niger CBS 513.88 NIT-Nc Nitrilase Neurospora crassa OR74A IRED-Str Imine reductase Streptomyces sp. IRED-Bc Imine reductase Bacillus cereus PAL-An Phenylalanine ammonia lyase photorhabdus luminescens PAL-Ss Phenylalanine ammonia lyase Solenostemon scutellarioides AADH-Bc Leucine dehydrogenase Bacillus cereus AADH-Bs Phenylalanine dehydrogenase Bacillus sphaericus

TABLE-US-00002 TA-Cv Sequence number Sequence Female parent SEQ ID NO:1 MQKQRTTSQWRELDAAHHLHPFTDTASLNQAGARVM TRGEGVYLWDSEGNKIIDGMAGLWCVNVGYGRKDFA EAARRQMEELPFYNTFFKTTHPAVVELSSLLAEVTPAG FDRVFYTNSGSESVDTMIRMVRRYWDVQGKPEKKTLI GRWNGYHGSTIGGASLGGMKYMHEQGDLPIPGMAHI EQPWWYKHGKDMTPDEFGWAARWLEEKILEIGADKV AAFVGEPIQGAGGVIVPPATYWPEIERICRKYDVLLVAD EVICGFGRTGEWFGHQHFGFQPDLFTAAKGLSSGYLPI GAVFVGKRVAEGLIAGGDFNHGFTYSGHPVCAAVAHA NVAALRDEGIVQRVKDDIGPYMQKRWRETFSRFEHVD DVRGVGMVQAFTLVKNKAKRELFPDFGEIGTLCRDIFF RNNLIMRACGDHIVSAPPLVMTRAEVDEMLAVAERCLE EFEQTLKARGLA Mutant1 (TA-Cv-V1) SEQ ID NO:2 R416T+T7C+S47C+Q380L Mutant 2 (TA-CV-V2) SEQ ID NO:3 R416T+T7C+S47C+R405E+K90G+A95P+K304D+Q380 L+I297L

TABLE-US-00003 TA-Ac Sequence number Sequence Female parent SEQ ID NO: 4 MGLTVQKINWEQVKEWDRKYLMRTFSTQNEYQPVPIES TEGDYLITPGGTRLLDFFNQLCCVNLGQKNQKVNAAIKE ALDRYGFVWDTYATDYKAKAAKIIIEDILGDEDWPGKVRF VSTGSEAVETALNIARLYTNRPLVVTREHDYHGWTGGA ATVTRLRSFRSGLVGENSESFSAQIPGSSCSSAVLMAPS SNTFQDSNGNYLKDENGELLSVKYTRRMIENYGPEQVA AVITEVSQGVGSTMPPYEYVPQIRKMTKELGVLWISDEV LTGFGRTGKWFGYQHYGVQPDIITMGKGLSSSSLPAGA VVVSKEIAAFMDKHRWESVSTYAGHPVAMAAVCANLEV MMEENLVEQAKNSGEYIRSKLELLQEKHKSIGNFDGYGL LWIVDIVNAKTKTPYVKLDRNFRHGMNPNQIPTQIIMEKA LEKGVLIGGAMPNTMRIGASLNVSRGDIDKAMDALDYAL DYLESGEWQQS Mutant 1 (TA-Ac-V1) SEQ ID NO: 5 L3S+V5S+C60Y+F164L+A178L+S187A+I180V+L370A+G 411D+S186G+Y384F+I389F+V252I+L404Q+E171D Mutant 2 (TA-Ac-V2) SEQ ID NO: 6 L3S+V5S+C60Y+F164L+A178L+S187A+I180V+L370A+G 411D+S186G+Y384F+I389F+V252I+E424Q+M423K

TABLE-US-00004 KRED-Ac Sequence number Sequence Female parent SEQ ID NO: 7 MARVAGKVAIVSGAANGIGKATAQLLAKEGAKWIGDLK EEDGQKAVAEIKAAGGEAAFVKLNVTDEAAWKAAIGQTL KLYGRLDIAVNNAGINYSGSVESTSLEDWRRVQSINLDG VFLGTQVAIEAMKKSGGGSIVNLSSISGLIGDPMLAAYVA SKGGVRLFTKSAALHCAKSGYKIRVNSVHPGYIWTPMVA GLTKEDAAARQKLVDLHPIGHLGEPNDIAYGILYLASDES KFVTGSELVIDGGYTAQ Mutant 1 (KRED-Ac-V1) SEQ ID NO: 8 E144S+A94N+N156V Mutant 2 (KRED-Ac-V2) SEQ ID NO: 9 E144S+A94T+N156T

TABLE-US-00005 CHMO-Rs Sequence number Sequence Female parent SEQ ID NO:10 MTAQISPTVVDAVVIGAGFGGIYAVHKLHNEQGLTVVGFDK ADGPGGTWYWNRYPGALSDTESHLYRFSFDRDLLQDGTWKTT YITQPEILEYLESVVDRFDLRRHFRFGTEVTSAIYLEDENLWEVST DKGEVYRAKYVVNAVGLLSAINFPDLPGLDTFEGETIHTAAWPEG KNLAGKRVGVIGTGSTGQQVITALAPEVEHLTVFVRTPQYSVPVG NRPVTKEQIDAIKADYDGIWDSVKKSAVAFGFEESTLPAMSVSEE ERNRIFQEAWDHGGGFRFMFGTFGDIATDEAANEAAASFIRSKIA EIIEDPETARKLMPTGLYAKRPLCDNGYYEVYNRPNVEAVAIKEN PIREVTAKGVVTEDGVLHELDVLVFATGFDAVDGNYRRIEIRGRN GLHINDHWDGQPTSYLGVTTANFPNWFMVLGPNGPFTNLPPSIE TQVEWISDTVAYAERNEIRAIEPTPEAEEEWTQTCTDIANATLFTR GDSWIFGANVPGKKPSVLFYLGGLGNYRNVLAGVVADSYRGFEL KSAVPVTA Mutant 1 (CHMO-Rs-V1) SEQ ID NO:11 F508Y+F435N+L438A+T436S+F280V+S441V Mutant 2 (CHMO-Rs-V2) SEQ ID NO:12 F508Y+F435N+L438A+T436S+F280V+S441V+L510V

TABLE-US-00006 CHMO-Rr Sequence number Sequence Female parent SEQ ID NO:13 MTTSIDREALRRKYAEERDKRIRPDGNDQYIRLDHVDGWSH DPYMPITPREPKLDHVTFAFIGGGFSGLVTAARLRESGVESV RIIDKAGDFGGVWYWNRYPGAMCDTAAMVYMPLLEETGYM PTEKYAHGPEILEHCQRIGKHYDLYDDALFHTEVTDLVWQEH DQRWRISTNRGDHFTAQFVGMGTGPLHVAQLPGIPGIESFR GKSFHTSRWDYDYTGGDALGAPMDKLADKRVAVIGTGATAV QCVPELAKYCRELYVVQRTPSAVDERGNHPIDEKWFAQIAT PGWQKRWLDSFTAIWDGVLTDPSELAIEHEDLVQDGWTALG QRMRAAVGSVPIEQYSPENVQRALEEADDEQMERIRARVDE IVTDPATAAQLKAWFRQMCKRPCFHDDYLPAFNRPNTHLVD TGGKGVERITENGVVVAGVEYEVDCIVYASGFEFLGTGYTDR AGFDPTGRDGVKLSEHWAQGTRTLHGMHTYGFPNLFVLQL MQGAALGSNIPHNFVEAARWAAIVDHVLSTGTSSVETTKEA EQAWVQLLLDHGRPLGNPECTPGYYNNEGKPAELKDRLNV GYPAGSAAFFRMMDHWLAAGSFDGLTFR Mutant 1 (CHMO-Rr-V1) SEQ ID NO:14 P190L + Y559M + C249V + C393V + C257A + M45T Mutant 2 (CHMO-Rr-V2) SEQ ID NO:15 Y559M + P190L + P504V

[0070] PB in the following embodiments represents a phosphate buffer.

Embodiment 1: Immobilized Transaminase

[0071] 1 g of an amino resin is taken, and washed with 20 mM of the phosphate buffer (PB for short, pH 7.0) for later use.

[0072] 160 .Math.L of a glutaraldehyde (50% of aqueous solution) is added to 4 mL of the PB buffer (20 mM, pH 7.0), and an appropriate ratio of PEG or PEI is added. After being incubated at a room temperature for 30-60 min, the above amino resin is added to the solution, and then it is incubated at 20-25° C. for 1-2 h. After being filtered, the modified amino resin is obtained, and then 4 mL of enzyme solution (20-25 mg/mL protein, including a main enzyme and a corresponding coenzyme thereof) is added to the modified amino resin, and then it is incubated at 20° C. for 16-24 h. Finally, it is washed with 20 mM PB (pH 8.0, and 0.5 M NaCl is contained) for 3 times.

[0073] Immobilized transaminase activity and reusability test:

##STR00009##

##STR00010##

[0074] In a 10 mL reaction flask, 0.3 mL of MeOH is added, 0.1 g of a main raw material 1 or a main raw material 2 is added, 4 eq of isopropylamine hydrochloride and 1.0 mg of pyridoxal-5′-phosphate (PLP) are added, and 0.1 M PB 7.0 is supplemented until a final volume of the reaction solution is 1 mL, 0.1 g of enzyme powder or cross-linked enzyme aggregate wet enzyme or cross-linked enzyme aggregate lyophilized powder prepared by 0.1 g of the enzyme powder is added, and it is stirred at 30° C. for 16-20 h. The conversion rate of the system is detected by a High Performance Liquid Chromatography (HPLC), the immobilized enzyme is separated after each round of the reaction, and reused in the next round of the reaction, and the number of repeated uses is investigated. Response data is as follows:

TABLE-US-00007 Enzyme Carrier Mass ratio of macromolecular polymer: cross-linking agent on carrier Conversion rate (%) Number of cycles TA-Af Carrier-free (free enzyme) -/- >97% 1 LX1000HA GA 80%-90% 5 PEG400:GA=10:1 >97% 4 PEG400:GA=5:1 >97% 8 PEG400:GA=2:1 >97% 8 PEG2000:GA=5:1 >97% 8 PEG2000:GA=2:1 >97% 9 PEG2000:GA=1:1 90% 9 PEG6000:GA=1:2 70% 8 PEG6000:GA=2:1 >97% 10 PEG6000:GA=5:1 >97% 9 PEG6000:GA=5:2 >97% 8 PEI (3 KDa):GA=3:1 >97% 6 PEI (3 KDa):GA=1:1 >97% 10 PEI (3 KDa):GA=1:5 92% 11 PEI (3 KDa):GA=1:7 75% 11 PEI (25 KDa):GA=1:1 >97% 8 PEI (25 KDa):GA=1.5:1 >97% 7 PEI (25 KDa):GA=1:2 >97% 9 PEI (70 KDa):GA=1:2 >97% 7 PEI (70 KDa):GA=1:3 90% 8 PEI (70 KDa):GA=1:5 85% 11 PEI (70 KDa):GA=1:7 75% 9 LX1000EPN GA 80% 5 PEG400:GA=2:1 70%-80% 3 PEG6000:GA=5:2 70%-80% 4 PEI (3 KDa):GA=1:1 70%-80% 10 PEI (3 KDa):GA=1:2 70%-80% 11 PEI (70 KDa):GA=1:5 80%-85% 11 ECR8409 GA 80% 2 PEG6000:GA=5:2 70%-80% 8 PEI (70 KDa):GA=1:5 80%-85% 8 ESR-1 GA <70% 2 PEG6000:GA=5:2 70%-80% 4 ESR-3 GA <70% 2 PEG6000:GA=5:2 70%-80% 3 TA-Ac Free enzyme -/ >97% 1 LX1000EA GA 80%-85% 4 PEG6000:GA=5:2 80%-90% 7 LX1000HA GA >97% 6 PEG6000:GA=5:2 >97% 12 PEI (3 KDa):GA=1:1 >97% 10 ESR-1 GA 80%-90% 4 PEG6000:GA=5:2 90%-95% 6 PEI (3 KDa):GA=1:1 90%-95% 6 ESR-8 GA 80%-85% 3 PEG6000:GA=5:2 90%-95% 5 LX1000EPN PEG6000:GA=5:2 >97% 10 TA-Ac-V1 LX1000HA PEG6000:GA=5:2 >97% 16 TA-Ac-V2 LX1000HA PEG6000:GA=5:2 >97% 19 TA-Cv Free enzyme -/ >97% 1 ECR8409 GA >97% 6 PEG6000:GA=5:2 >97% 8 PEI (3 KDa):GA=1:1 >97% 8 ECR8404 PEI (70 KDa):GA=1:5 >97% 7 GA >97% 4 PEG6000:GA=5:2 >97% 7 PEI (3 KDa):GA=1:1 >97% 7 ECR8315 GA >97% 4 PEG6000:GA=5:2 >97% 8 PEI (3 KDa):GA=1:1 >97% 7 LX1000HA GA >97% 6 PEG6000:GA=5:2 >97% 7 PEI (3 KDa):GA=1:1 >97% 9 PEI (25 KDa):GA=1:5 >97% 10 LX1000EPN GA >97% 6 PEG6000:GA=5:2 >97% 7 PEI (3 KDa):GA=1:1 >97% 7 ESR-01 GA >97% 4 PEG6000:GA=5:2 >97% 6 PEI (3 KDa):GA=1:1 >97% 7 ESR-03 GA >97% 4 PEG6000:GA=5:2 >97% 5 PEI (3 KDa):GA=1:1 >97% 5 TA-Cv-V1 LX1000HA PEI (25 KDa):GA=1:5 >97% 16 PEG6000:GA=5:2 >97% 19 TA-Cv-V2 LX1000HA PEG6000:GA=5:2 >97% 22

Embodiment 2: Conversion Rate and Reusability Test of Immobilized Ketoreductase

[0075] An immobilization method is the same as in Embodiment 1.

[0076] Immobilized enzyme activity and reusability detection:

##STR00011##

##STR00012##

[0077] In a 10 mL reaction flask, 0.5 mL of isopropanol (IPA) is added, 0.1 g of a main raw material 3 or 4 is dissolved, 0.5 mL of 0.1 M PB 7.0 and 1-10 mg of nicotinamide adenine dinucleotide (NAD+) are added, then 0.05 g of enzyme powder or the immobilized enzyme prepared by 0.1-0.3 g of the enzyme powder is added. It is stirred at 30° C. for 16-20 h. The conversion rate of the system is detected by a Gas Chromatography (GC), the immobilized enzyme is separated after each round of the reaction, and reused in the next round of the reaction, and the number of repeated uses is investigated. Response data is as follows:

TABLE-US-00008 Enzyme Carrier Mass ratio of macromolecular polymer: cross-linking agent on carrier Conversion rate (%) Number of cycles KRED-Ac Carrier-free (free enzyme) -/ >99% 1 LX1000HA GA >99% 5 PEG6000:GA=5:2 >99% 9 PEI (3 KDa):GA=1:1 >99% 10 PEI (3 KDa):GA=1:2 >99% 10 PEI (70 KDa):GA=1:5 >99% 10 LX1000EA GA >99% 2 PEG6000:GA=5:2 >99% 5 PEI (3 KDa):GA=1:1 >99% 6 LX1000EPN GA >99% 4 PEG6000:GA=5:2 >99% 7 PEI (3 KDa):GA=1:2 >99% 7 ESR-1 GA >99% 3 PEI (3 KDa):GA=1:1 >99% 5 ESR-3 GA >99% 2 PEI (3 KDa):GA=1:1 >99% 5 ESR-8 GA >99% 2 PEI (3 KDa):GA=1:1 >99% 4 KRED-Ac-V1 LX1000EPN PEG6000:GA=5:2 >99% 12 PEI (3 KDa):GA=1:1 >99% 15 KRED-Ac-V2 LX1000EPN PEG6000:GA=5:2 >99% 15 KRED-Cm Free enzyme -/- 90% 1 LX1000EA GA 50%-55% 4 PEG6000:GA=5:2 80% 3 LX1000HA GA 75% 3 PEG6000:GA=5:2 75% 6 PEI (3 KDa):GA=1:1 75% 5 ESR-1 GA 50% 4 PEG6000:GA=5:2 70% 6 PEI (3 KDa):GA=1:1 70% 6 ESR-8 GA 75% 3 PEG6000:GA=5:2 75% 6

Embodiment 3: Conversion Rate and Reusability Test of Immobilized CHMOs

[0078] An immobilization method is the same as in Embodiment 1.

[0079] The activity of the CHMO amino carrier immobilized enzyme is detected by reacting with the following substrate 5

##STR00013##

[0080] 0.3 mL of isopropanol is loaded in a 10 ml reaction flask, and then 500 mg of the substrate 5, and 3 mL of 0.1 M PB (pH 8.0) containing 5 mg of nicotinamide adenine dinucleotide phosphate (NADP+) are added, then 50 mg of alcohol dehydrogenase ADH-Tb free enzyme and 100-200 mg of CHMO amino carrier co-immobilized enzyme (wet, containing 50-80% of water) are added. It is reacted at 30° C. for 16-20 hours, and the conversion rate is tested. The immobilized enzyme is separated after each round of the reaction, and reused in the next round of the reaction, and the number of repeated uses is investigated. Results are shown in the table below.

TABLE-US-00009 Enzyme Carrier Mass ratio of macromolecular polymer: cross-linking agent on carrier Conversion rate (%) Number of cycles CHMO-Bp Carrier-free (free enzyme) -/ >98% 1 LX1000HA GA 80% 5 PEG400:GA=2:1 95% 7 PEG2000:GA=2:1 95% 6 PEG6000:GA=2:1 95% 6 PEG6000:GA=5:2 95% 7 PEI (3 KDa):GA=1:1 95% 6 PEI (25 KDa):GA=1:2 95% 8 PEI (70 KDa):GA=1:5 95% 8 LX1000EPN GA 80% 4 PEG400:GA=2:1 95% 7 PEG6000:GA=5:2 95% 6 PEI (3 KDa):GA=I:I 95% 5 PEI (3 KDa):GA=I:2 95% 7 PEI (70 KDa):GA=1:5 95% 8 ECR8415 GA 80% 4 PEG6000:GA=5:2 95% 7 PEI (70 KDa):GA=1:5 95% 6 LX1000NH GA 80% 4 PEG6000:GA=5:2 95% 6 ESR-8 GA 80% 5 PEG6000:GA=5:2 95% 7 CHMO-Rr Free enzyme -/ >98% 1 LX1000EA GA 90% 5 PEG6000:GA=5:2 98% 8 LX1000HA GA 90% 6 PEG6000:GA=5:2 98% 9 PEI (3 KDa):GA=1:1 98% 8 ECR8409 GA 90% 6 PEG6000:GA=5:2 98% 8 PEI (3 KDa):GA=1:1 98% 8 ESR-8 GA 90% 5 PEG6000:GA=5:2 98% 7 CHMO-Rr-V1 ECR8409 PEG6000:GA=5:2 98% 11 CHMO-Rr-V2 ECR8409 PEG6000:GA=5:2 98% 14 CHMO-Rs Free enzyme -/ >97% 1 ECR8409 GA 90% 7 PEG6000:GA=5:2 98% 9 PEI (3 KDa):GA=1:1 98% 9 ECR8315 GA 90% 4 PEG6000:GA=5:2 98% 8 PEI (3 KDa):GA=1:1 98% 7 LX1000HA GA 90% 6 PEG6000:GA=5:2 98% 8 PEI (3 KDa):GA=1:1 98% 8 PEI (25 KDa):GA=1:5 98% 9 LX1000EPN GA 90% 5 PEG6000:GA=5:2 98% 7 PEI (3 KDa):GA=1:1 98% 7 HM100D GA 90% 4 PEG6000:GA=5:2 98% 5 PEI (3 KDa):GA=1:1 98% 5 CHMO-Rs-V1 LX1000EPN PEI (25 KDa):GA=1:5 98% 10 CHMO-Rs-V2 LX1000EPN PEI (25 KDa):GA=1:5 98% 14

Embodiment 4: Conversion Rate and Reusability Test of Immobilized EREDs

[0081] An immobilization method is the same as in Embodiment 1.

[0082] The activity of the ERED amino carrier immobilized enzyme is detected by reacting with the following substrate 6:

##STR00014##

[0083] 3 mL of 0.1 M PB (pH 7.0-8.0) is loaded in a 10 ml reaction flask, and then 100 mg of the substrate 6 is added, and 10 mg of nicotinamide adenine dinucleotide phosphate (NAD (P)+), 80 mg of an ammonium formate, 20 mg of FDH and 100 mg of ERED immobilized enzyme are added. It is reacted at 30° C. for 16-20 hours, and the conversion rate is tested. The immobilized enzyme is separated after each round of the reaction, and reused in the next round of the reaction, and the number of repeated uses is investigated. Test results are shown in the table below.

TABLE-US-00010 Enzyme Carrier Mass ratio of macromolecular polymer: cross-linking agent on carrier Conversion rate (%) Number of cycles ERED-Sc Carrier-free (free enzyme) -/ >90% 1 LX1000HA GA >90% 6 PEG6000:GA=5:2 >90% 8 PEI (3 KDa):GA=1:1 >90% 8 PEI (3 KDa):GA=1:2 >90% 9 PEI (70 KDa):GA=1:5 >90% 10 LX1000EPN GA >90% 6 PEG6000:GA=5:2 >90% 9 PEI (3 KDa):GA=1:2 >90% 9 ECR8409 GA >90% 7 PEI (3 KDa):GA=1:2 >90% 10 ESR-8 GA >90% 5 PEI (70 KDa):GA=1:5 >90% 7 ERED-Chr Free enzyme -/ >90% 1 LX1000EA GA >90% 6 PEG6000:GA=5:2 >90% 8 LX1000HA GA >90% 5 PEG6000:GA=5:2 >90% 8 PEI (3 KDa):GA=1:2 >90% 8 ECR8309 GA >90% 6 PEG6000:GA=5:2 >90% 8 PEI (3 KDa):GA=1:1 >90% 8 ESR-3 GA >90% 5 PEG6000:GA=5:2 >90% 7

Embodiment 5: Conversion Rate and Reusability Test of Immobilized NITs

[0084] An immobilization method is the same as in Embodiment 1.

[0085] The activity of the NIT amino carrier immobilized enzyme is detected by reacting with the following substrate 7

##STR00015##

[0086] 2 mL of 0.1 M PB buffer (pH 7.0-8.0) is added to a 10 mL reaction flask, and 100 mg of the above substrate 9 is added, then the amino carrier immobilized enzyme containing 200 mg of NIT is added. After it is reacted at 30° C. for 16 hours, the conversion rate is detected. The immobilized enzyme is separated after each round of the reaction, and reused in the next round of the reaction, and the number of repeated uses is investigated. Test results are shown in the table below.

TABLE-US-00011 Enzyme Carrier Mass ratio of macromolecular polymer: cross-linking agent on carrier Conversion rate (%) Number of cycles NIT-An Carrier-free (free enzyme) –/– >98% 1 LX1000HA GA >98% 3 PEG6000:GA=5:2 >98% 6 PEI (3 KDa):GA=1:1 >98% 5 PEI (3 KDa):GA=1:2 >98% 6 PEI (70 KDa):GA=1:5 >98% 6 LX1000EPN GA >98% 3 PEG6000:GA=5:2 >98% 5 PEI (3 KDa):GA=1:2 >98% 5 ECR8409 GA >98% 3 PEI (3 KDa):GA=1:2 >98% 5 NIT-Nc Free enzyme –/– >98% 1 LX1000HA GA >98% 3 PEG6000:GA=5:2 >98% 6 PEI (3 KDa):GA=1:1 >98% 5 ECR8409 GA >98% 4 PEG6000:GA=5:2 >98% 6 PEI (3 KDa):GA=1:1 >98% 6 ESR-1 GA >98% 3 PEG6000:GA=5:2 >98% 6

Embodiment 6: Conversion Rate and Reusability Test of Immobilized IREDs

[0087] An immobilization method is the same as in Embodiment 1.

[0088] The activity of the IRED amino carrier immobilized enzyme is detected by reacting with the following substrate 8

##STR00016##

[0089] 2 mL of 0.1 M PB buffer (pH 7.0-8.0) is added to a 10 mL reaction flask, and then 100 mg of the above substrate 8, 10 mg of NAD+, 60 mg of an ammonium formate, 10 mg of FDH and the immobilized enzyme containing 400 mg of the IRED amino carrier is added. After it is reacted at 30° C. for 20 hours, the conversion rate is detected. The immobilized enzyme is separated after each round of the reaction, and reused in the next round of the reaction, and the number of repeated uses is investigated. Test results are shown in the table below.

TABLE-US-00012 Enzyme Carrier Mass ratio of macromolecular polymer: cross-linking agent on carrier Conversion rate (%) Number of cycles IRED-Str Carrier-free (free enzyme) –/– >98% 1 LX1000HA GA >90% 2 PEG6000:GA=5:2 >90% 3 PEI (70 KDa):GA=1:5 >90% 3 LX1000EPN GA >90% 2 PEG6000:GA=5:2 >90% 3 PEI (3 KDa):GA=1:2 >90% 3 ECR8409 GA >90% 2 PEI (3 KDa):GA=1:1 >90% 4 ESR-1 GA >90% 2 PEI (3 KDa):GA=1:1 >90% 5 IRED-Bc Free enzyme –/– >90% 1 LX1000EPN GA >90% 3 PEG6000:GA=5:2 >90% 5 LX1000HA GA >90% 3 PEG6000:GA=5:2 >90% 5 PEI (3 KDa):GA=1:2 >90% 5 ECR8309 GA >90% 3 PEG6000:GA=5:2 >90% 4 PEI (3 KDa):GA=1:1 >90% 4 ECR8409 GA >90% 3 PEG6000:GA=5:2 >90% 5

Embodiment 7: Conversion Rate and Reusability Test of Immobilized PALs

[0090] An immobilization method is the same as in Embodiment 1.

[0091] The activity of the PAL amino carrier immobilized enzyme is detected by reacting with the following substrate 9

##STR00017##

[0092] 8 mL of 4 M ammonium carbamate aqueous solution (pH 9.0-9.5) is added to a 10 mL reaction flask, 100 mg of the above substrate 10 is added, and then the immobilized enzyme containing 400 mg of NIT is added. After it is reacted at 30° C. for 16-20 hours, the conversion rate is detected. The immobilized enzyme is separated after each round of the reaction, and reused in the next round of the reaction, and the number of repeated uses is investigated. Test results are shown in the table below.

TABLE-US-00013 Enzyme Carrier Mass ratio of macromolecular polymer: cross-linking agent on carrier Conversion rate (%) Number of cycles PAL-An Carrier-free (free enzyme) -/- 80% 1 LX1000HA GA 80% 4 PEG6000:GA=5:2 80% 5 PEI (70 KDa):GA=1:5 80% 6 LX1000EA GA 80% 4 PEG6000:GA=5:2 80% 5 PEI (3 KDa):GA=1:1 80% 5 LX1000EPN GA 80% 6 PEG6000:GA=5:2 80% 8 PEI (3 KDa):GA=1:2 80% 8 ECR8309 GA 80% 6 PEI (3 KDa):GA=1:1 80% 7 ECR8315 GA 80% 6 PEI (3 KDa):GA=1:1 80% 8 ESR-8 GA 80% 5 PEI (3 KDa):GA=1:1 80% 7 PAL-Ss Free enzyme -/- 80% 1 LX1000EA GA 80% 6 PEG6000:GA=5:2 80% 9 LX1000HA GA 80% 6 PEG6000:GA=5:2 80% 8 PEI (3 KDa):GA=1:1 80% 8 LX1000EPN GA 80% 9 PEG6000:GA=5:2 80% 12 PEI (3 KDa):GA=1:1 80% 12 ECR8309 GA 80% 9 PEG6000:GA=5:2 80% 11

Embodiment 8: Conversion Rate and Reusability Test of Immobilized AADHs

[0093] ##STR00018##

##STR00019##

##STR00020##

[0094] In a 10 mL reaction flask, 5 mL of 0.1 M Tris-CI (pH 8.0-9.0) is added, then 100 mg of the main raw material 10, 11 or 12, and 108 mg of an ammonium chloride are added, a pH is adjusted to 7.5-8.0, then 10-50 mg of NAD+, 50 mg of GDH, and 100 mg of an AADH enzyme (or immobilized AADH prepared by 100-300 mg of a free enzyme) are added. After it is reacted at 30° C. for 16-20 h, it is used for a conversion rate test. Test results are shown in the table below.

TABLE-US-00014 Enzyme Carrier Mass ratio of macromolecular polymer: cross-linking agent on carrier Conversion rate (%) Number of cycles AADH-Bc Carrier-free (free enzyme) –/– >99% 1 LX1000HA GA >99% 8 PEG6000:GA=5:2 >99% 12 PEI (3 KDa):GA=1:1 >99% 12 LX1000EA GA >99% 5 PEG6000:GA=5:2 >99% 7 ECR8409 GA >99% 10 PEG6000:GA=5:2 >99% 14 ESR-1 GA >99% 7 PEG6000:GA=5:2 >99% 10 ESR-3 GA >99% 7 PEG6000:GA=5:2 >99% 9 AADH-Bs Free enzyme –/– >99% 1 LX1000EA GA >99% 6 PEG6000:GA=5:2 >99% 9 LX1000HA GA >99% 9 PEG6000:GA=5:2 >99% 12 PEI (3 KDa):GA=1:1 >99% 11 ESR-1 GA >99% 8 PEG6000:GA=5:2 >99% 12 PEI (3 KDa):GA=1:1 >99% 11 ESR-8 GA >99% 6 PEG6000:GA=5:2 >99% 8

Embodiment 9: Application of Transaminase Amino Carrier Immobilized Enzyme in Packed Bed continuous reaction

[0095] In Embodiment 1, a transaminase TA-Cv is immobilized on a carrier LX1000HA, a cross-linking agent GA is modified by PEI (3 KDa):GA=1:1, and the obtained immobilized enzyme is filled into a column-shaped reactor with a column volume of 120 mL, and the amount of the immobilized enzyme used is 72 g.

[0096] 500 g of the substrate 1 is dissolved with 1.5 L of methanol, and 4 eq of an isopropylamine hydrochloride (1.8 L of 6 M isopropylamine hydrochloride in water) and 5 g of PLP are added without adding a PB buffer (0.1 M, pH 8.0), and the volume is fixed to 5 L.

[0097] The flow rate is set to 0.6 mL/min, namely the retention time is 200 min, a continuous reaction is performed, effluent liquid at an outlet is tested for the conversion rate, and the conversion rate is > 98%. After 400 h of continuous operation, the conversion rate is not decreased. After 420 h of the operation, the conversion rate is decreased to 89%. See the table below for details.

TABLE-US-00015 Enzyme Carrier Immobilized enzyme amount Column volume Retention time Operation time Conversion rate TA-Cv-V1 LX1000HA 72 g 120 mL 200 min 400 h 97.5% 420 h 89%

Embodiment 10: Application of Transaminase Immobilized Enzyme in Continuous Stirred Tank reaction

[0098] The same immobilized enzyme TA-Ac in Embodiment 1 is used, the carrier is ECR8409, and the used cross-linking agent GA is modified with PEG6000:GA=5:2. 50 g of the immobilized enzyme of transaminase TA-Ac is added to a 200 mL reactor, and 150 mL of a phosphate buffer is added.

[0099] 500 g of the substrate 1 is added with 3.2 L of PB (0.1 M, pH 7.0), 1.8 L of isopropylamine hydrochloride aqueous solution (6 M) and 5 g of PLP, and it is beaten to prepare suspension.

[0100] The substrate suspension is continuously added to a reaction flask at a rate of 0.4 mL/min (namely the retention time is 500 min), and a reaction system is extracted from an outlet at the same flow rate (a filter heat is added at a tail end of a pipe to prevent the immobilized enzyme from being extracted). Under this condition, the conversion rate may reach more than 90%, and the conversion rate is basically not reduced after continuous operation for 400 h. Results are shown in the table below.

TABLE-US-00016 Enzyme Carrier Immobilized enzyme amount Reactor volume Retention time Operation time Conversion rate TA-Cv ECR8409 50 g 200 mL 250 min 400 h >90% 424 h 82%

Embodiment 11

[0101] According to the ammonia lyase PAL-Ss immobilized enzyme prepared in Embodiment 7, the carrier is LX1000EPN, and the cross-linking agent is modified with PEG6000:GA=5:2. 6 g of the obtained immobilized enzyme is filled into a 10 mL column-shaped reactor.

[0102] 500 g of the substrate 9 is dissolved with 4.5 L of ammonium carbamate aqueous solution (4 M, pH 9.0-9.5).

[0103] The flow rate is set to 0.03 mL/min, namely the retention time is 330 min, and a continuous reaction is performed. Effluent liquid at an outlet is tested for the conversion rate, and the conversion rate is 80%. After 360 h of continuous operation, the conversion rate is not decreased, and after 400 h of the operation, the conversion rate is decreased to 72%. See the table below.

TABLE-US-00017 Enzyme Carrier Immobilized enzyme amount Column volume Retention time Operation time Conversion rate PAL-Ss LX1000EPN 6 g 10 mL 100 min 360 h 80% 400 h 72%

Embodiment 12

[0104] According to the ketoreductase KRED-Ac immobilized enzyme prepared in Embodiment 2, the carrier is LX1000HA, and the cross-linking agent is modified by PEI (3 KDa):GA=1:2. 6 g of the obtained immobilized enzyme is filled into a 10 mL column-shaped reactor.

[0105] 100 g of the substrate 3 is dissolved with 0.3 L of isopropanol, and 0.7 L of PB buffer (0.1 M, pH 7.0) is added to dissolve, and then 0.1 g of NAD + is added.

[0106] The flow rate is set to 0.05 mL/min, namely the retention time is 200 min, and a continuous reaction is performed. Effluent liquid at an outlet end is detected for the conversion rate, and the conversion rate is >90%. The conversion rate is not reduced after 200 h of continuous operation, and the conversion rate is reduced to 84% after 220 h of the operation. See the table below.

TABLE-US-00018 Reaction result of KRED-Ac immobilized enzyme in packed bed continuous reaction Enzyme carrier Immobilized enzyme amount Column volume Retention time Operation time Conversion rate KRED-AC+GDH LX1000HA 5.9 g 10 mL 100 min 200 h 90% 220 h 84%

[0107] From the above description, it may be seen that the above embodiments of the present invention achieve the following technical effects: the amino resin carrier is modified by using the cross-linking agent treated with the macromolecular polymer, it is beneficial to make the enzyme immobilized on it to form a network cross-linking, thereby the immobilization effect of the enzyme is more stable, and the recycling efficiency of the enzyme is improved.

[0108] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and changes. Any modifications, equivalent replacements, improvements and the like made within the spirit and principle of the present invention shall be included within a scope of protection of the present invention.